Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA UCSF
Dates
study started
study ends around
Principal Investigator
by Michael D Geschwind, MD (ucsf)
Headshot of Michael D Geschwind
Michael D Geschwind

Description

Summary

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.

Official Title

Unraveling the Early Phases of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)

Details

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic vascular dementia. Individuals with CADASIL are destined to develop vascular cognitive impairment and dementia (VCID), which can be studied in pre-symptomatic and prodromal disease stages to detect the earliest changes in biological fluids, neuroimaging, and the emerging phenotype of symptomatic VCID.

The objective of the proposed research is to exploit an autosomal dominant vascular dementia as a model to investigate specific features of VCID and to examine interactions with risk factors impacting the aging life course.

The study will enroll a total of 575 participants with a CADASIL family history who have had a genetic test for a NOTCH3 variant. Participants will complete: a clinical interview, a neurological exam, neurocognitive and behavior assessments, MRI, and a blood draw at each study visit. Participants will complete 3 in-person visits in total as part of this study: baseline, visit 2 (18 months after baseline), visit 3 (36 months after baseline). Additional contact will occur by phone, mail, email or the internet as needed and will be referred to as "remote visits".

Keywords

CADASIL, neurodegeneration, dementia, cognitive impairment, NOTCH3, vascular dementia, Leukoencephalopathies, Multi-Infarct Dementia, Study Procedures

Eligibility

Locations

  • University of California accepting new patients
    Los Angeles California 90095 United States
  • University of California accepting new patients
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Michael D Geschwind, MD (ucsf)
    Dr. Geschwind received his M.D.and Ph.D. in neuroscience through the National Institutes of Health (NIH)-sponsored Medical Scientist Training Program (MSTP) at the Albert Einstein College of Medicine in New York.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Wisconsin, Madison
ID
NCT05677880
Study Type
Observational
Participants
Expecting 575 study participants
Last Updated